Literature DB >> 10348420

A Bayesian approach to stochastic cost-effectiveness analysis.

A H Briggs1.   

Abstract

The aim of this paper is to briefly outline a Bayesian approach to cost-effectiveness analysis (CEA). Historically, frequentists have been cautious of Bayesian methodology, which is often held as synonymous with a subjective approach to statistical analysis. In this paper, the potential overlap between Bayesian and frequentist approaches to CEA is explored--the focus being on the empirical and uninformative prior-based approaches to Bayesian methods rather than the use of subjective beliefs. This approach emphasizes the advantage of a Bayesian interpretation for decision-making while retaining the robustness of the frequentist approach. In particular the use of cost-effectiveness acceptability curves is examined. A traditional frequentist approach is equivalent to a Bayesian approach assuming no prior information, while where there is pre-existing information available from which to construct a prior distribution, an empirical Bayes approach is equivalent to a frequentist approach based on pooling the available data. Cost-effectiveness acceptability curves directly address the decision-making problem in CEA. Although it is argued that their interpretation as the probability that an intervention is cost-effective given the data requires a Bayesian interpretation, this should generate no misgivings for the frequentist.

Mesh:

Year:  1999        PMID: 10348420     DOI: 10.1002/(sici)1099-1050(199905)8:3<257::aid-hec427>3.0.co;2-e

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  45 in total

Review 1.  Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio.

Authors:  A O'Hagan; J W Stevens; J Montmartin
Journal:  Pharmacoeconomics       Date:  2000-04       Impact factor: 4.981

Review 2.  Handling uncertainty in cost-effectiveness models.

Authors:  A H Briggs
Journal:  Pharmacoeconomics       Date:  2000-05       Impact factor: 4.981

Review 3.  Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies.

Authors:  Niklas Zethraeus; Magnus Johannesson; Bengt Jönsson; Mickael Löthgren; Magnus Tambour
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 4.  Sample size determination for cost-effectiveness trials.

Authors:  Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

5.  A Bayesian network approach to the study of historical epidemiological databases: modelling meningitis outbreaks in the Niger.

Authors:  A Beresniak; E Bertherat; W Perea; G Soga; R Souley; D Dupont; S Hugonnet
Journal:  Bull World Health Organ       Date:  2012-01-20       Impact factor: 9.408

6.  Choice of statistical model for cost-effectiveness analysis and covariate adjustment: empirical application of prominent models and assessment of their results.

Authors:  Theodoros Mantopoulos; Paul M Mitchell; Nicky J Welton; Richard McManus; Lazaros Andronis
Journal:  Eur J Health Econ       Date:  2015-10-07

Review 7.  Information created to evade reality (ICER): things we should not look to for answers.

Authors:  Stephen Birch; Amiram Gafni
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 8.  The contrast and convergence of Bayesian and frequentist statistical approaches in pharmacoeconomic analysis.

Authors:  Grant H Skrepnek
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

9.  Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies.

Authors:  Simon Eckermann; Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2011-07       Impact factor: 4.981

10.  Bayesian Methods for Calibrating Health Policy Models: A Tutorial.

Authors:  Nicolas A Menzies; Djøra I Soeteman; Ankur Pandya; Jane J Kim
Journal:  Pharmacoeconomics       Date:  2017-06       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.